KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagannath, Sundar, Lin, Yi, Goldschmidt, Hartmut, Reece, Donna, Nooka, Ajay, Senin, Alicia, Rodriguez-Otero, Paula, Powles, Ray, Matsue, Kosei, Shah, Nina, Anderson, Larry D., Streetly, Matthew, Wilson, Kimberly, Le, Hoa Van, Swern, Arlene S., Agarwal, Amit, Siegel, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213772/
https://www.ncbi.nlm.nih.gov/pubmed/34145225
http://dx.doi.org/10.1038/s41408-021-00507-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213772/
https://www.ncbi.nlm.nih.gov/pubmed/34145225
http://dx.doi.org/10.1038/s41408-021-00507-2

Ejemplares similares